Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
5.53
-0.15 (-2.64%)
At close: Mar 3, 2026, 4:00 PM EST
5.55
+0.02 (0.36%)
After-hours: Mar 3, 2026, 7:49 PM EST
Compass Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Compass Therapeutics stock have an average target of 14.43, with a low estimate of 6.00 and a high estimate of 30. The average target predicts an increase of 160.94% from the current stock price of 5.53.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 6, 2026.
Analyst Ratings
The average analyst rating for Compass Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 5 | 5 | 4 |
| Buy | 3 | 3 | 3 | 5 | 6 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 10 | 11 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +442.50% | Jan 6, 2026 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 5, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 3, 2025 |
| Citizens | Citizens | Buy Initiates $10 | Buy | Initiates | $10 | +80.83% | Dec 3, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +80.83% | Dec 3, 2025 |
Financial Forecast
Revenue This Year
n/a
from 850.00K
Revenue Next Year
7.73M
EPS This Year
-0.44
from -0.36
EPS Next Year
-0.46
from -0.44
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 41.3M | ||||
| Avg | n/a | 7.7M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.38 | -0.22 | ||||
| Avg | -0.44 | -0.46 | ||||
| Low | -0.58 | -0.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.